![]() | License: Creative Commons Attribution 4.0 PDF - Published Version (3MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-535826
- DOI to cite this document:
- 10.5283/epub.53582
Abstract
(1) Background: T-cell immunoglobulin and ITIM domain (TIGIT) is a potential immunotherapeutic target in a variety of malignant entities, and antibody-based treatments are currently under investigation in clinical trials. While promising results were observed in patients with lung cancer, the role of TIGIT in oral squamous cell carcinoma (OSCC) as a biomarker as well as a therapeutic target ...

Owner only: item control page